EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC 3.0

Longitudinal Comparative Analysis of Circulating Tumor DNA and Matched Tumor Tissue DNA in Patients with Metastatic Colorectal Cancer Receiving Palliative First-Line Systemic Anti-Cancer Therapy

Seung-Been Lee, Ji-Won Kim, Hong-Geun Kim, Sung-Hyun Hwang, Kui-Jin Kim, Ju Hyun Lee, Jeongmin Seo, Minsu Kang, Eun Hee Jung, Koung Jin Suh, Se Hyun Kim, Jin Won Kim und 4 weitere

Cancer Research and Treatment · 2024

DOI: 10.4143/crt.2024.016 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cancer Research and Treatment, 2024. Verfasst von Seung-Been Lee und 15 weiteren Autor:innen. Beteiligte Einrichtung: Macrogen, Inc., Seoul, Korea. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Clonal Evolution, Colorectal Neoplasms, DNA Mutational Analysis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Ministry of Trade, Industry and Energy, Ministry of SMEs and Startups.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study aimed to compare tumor tissue DNA (ttDNA) and circulating tumor DNA (ctDNA) to explore the clinical applicability of ctDNA and to better understand clonal evolution in patients with metastatic colorectal cancer undergoing palliative first-line systemic therapy.Materials and Methods We performed targeted sequencing analysis of 88 cancer-associated genes using germline DNA, ctDNA at baseline (baseline-ctDNA), and ctDNA at progressive disease (PD-ctDNA). The results were compared with ttDNA data.

Results

Among 208 consecutively enrolled patients, we selected 84 (41 males; median age, 59 years; range, 35 to 90 years) with all four sample types available. A total of 202 driver mutations were found in 34 genes. ttDNA exhibited the highest mutation frequency (n=232), followed by baseline-ctDNA (n=155) and PD-ctDNA (n=117). Sequencing ctDNA alongside ttDNA revealed additional mutations in 40 patients (47.6%). PD-ctDNA detected 13 novel mutations in 10 patients (11.9%) compared to ttDNA and baseline-ctDNA. Notably, seven mutations in five patients (6.0%) were missense or nonsense mutations in APC, TP53, SMAD4, and CDH1 genes. In baseline-ctDNA, higher maximal variant allele frequency (VAF) values (p=0.010) and higher VAF values of APC (p=0.012), TP53 (p=0.012), and KRAS (p=0.005) mutations were significantly associated with worse overall survival.

Conclusion

While ttDNA remains more sensitive than ctDNA, our ctDNA platform demonstrated validity and potential value when ttDNA was unavailable. Post-treatment analysis of PD-ctDNA unveiled new pathogenic mutations, signifying cancer’s clonal evolution. Additionally, baseline-ctDNA’s VAF values were prognostic after treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNAClonal EvolutionColorectal NeoplasmsDNA Mutational AnalysisDNA, NeoplasmAdultAgedAged, 80 and overHumansMaleMiddle AgedAntineoplastic AgentsGene FrequencyHigh-Throughput Nucleotide SequencingKaplan-Meier EstimateLongitudinal StudiesMutation RateNeoplasm MetastasisPalliative CarePredictive Value of TestsPrognosisProgression-Free SurvivalReproducibility of ResultsFemaleAdenomatous Polyposis Coli Protein

Stichwörter der Autor:innen

Anti-cancer therapyCirculating tumor DNAClonal evolutionColorectal neoplasms

Substanzen

Antineoplastic AgentsCirculating Tumor DNADNA, NeoplasmAPC protein, humanAdenomatous Polyposis Coli ProteinCDH1 protein, humanAntigens, CDCadherinsKRAS protein, humanProto-Oncogene Proteins p21(ras)

Autor:innen und Institutionen

  • Macrogen, Inc., Seoul, Korea.
  • Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
  • Biomedical Research Institute, Seoul National University Bundang Hospital, Seongnam, Korea.
  • Department of Statistics, Hankuk University of Foreign Studies, Yongin, Korea.

Förderung

  • Ministry of Trade, Industry and Energy
  • Ministry of SMEs and Startups

Zitieren

APA

Lee, S. B., Kim, J. W., Kim, H. G., Hwang, S. H., Kim, K. J., Lee, J. H., Seo, J., Kang, M., Jung, E. H., Suh, K. J., Kim, S. H., Kim, J. W., Kim, Y. J., Kim, J. H., Kwon, N. J., & Lee, K. W. (2024). Longitudinal Comparative Analysis of Circulating Tumor DNA and Matched Tumor Tissue DNA in Patients with Metastatic Colorectal Cancer Receiving Palliative First-Line Systemic Anti-Cancer Therapy. Cancer Research and Treatment. https://doi.org/10.4143/crt.2024.016

Vancouver

Lee SB, Kim JW, Kim HG, Hwang SH, Kim KJ, Lee JH, et al. Longitudinal Comparative Analysis of Circulating Tumor DNA and Matched Tumor Tissue DNA in Patients with Metastatic Colorectal Cancer Receiving Palliative First-Line Systemic Anti-Cancer Therapy. Cancer Research and Treatment. 2024. doi:10.4143/crt.2024.016

BibTeX
@article{Lee2024,
  author = {Lee, Seung-Been and Kim, Ji-Won and Kim, Hong-Geun and Hwang, Sung-Hyun and Kim, Kui-Jin and Lee, Ju Hyun and Seo, Jeongmin and Kang, Minsu and Jung, Eun Hee and Suh, Koung Jin and Kim, Se Hyun and Kim, Jin Won and Kim, Yu Jung and Kim, Jee Hyun and Kwon, Nak-Jung and Lee, Keun-Wook},
  title = {Longitudinal Comparative Analysis of Circulating Tumor DNA and Matched Tumor Tissue DNA in Patients with Metastatic Colorectal Cancer Receiving Palliative First-Line Systemic Anti-Cancer Therapy},
  journal = {Cancer Research and Treatment},
  year = {2024},
  doi = {10.4143/crt.2024.016}
}
Kostenlos starten →